Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Merck call volume above normal and directionally bullish » 12:25
04/16/21
04/16
12:25
04/16/21
12:25
MRK

Merck

$77.30 /

+0.63 (+0.82%)

Bullish option flow…

Bullish option flow detected in Merck with 14,808 calls trading, 1.4x expected, and implied vol increasing over 2 points to 22.07%. May-21 80 calls and 5/14 weekly 72.5 puts are the most active options, with total volume in those strikes near 6,900 contracts. The Put/Call Ratio is 0.41. Earnings are expected on April 29th.

ShowHide Related Items >><<
MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

Recommendations
Atea selloff on Merck update unwarranted, says William Blair » 08:59
04/16/21
04/16
08:59
04/16/21
08:59
AVIR

Atea Pharmaceuticals

$46.01 /

-8.315 (-15.31%)

, MRK

Merck

$76.67 /

+0.27 (+0.35%)

William Blair analyst Tim…

William Blair analyst Tim Lugo says the weakness yesterday in shares of Atea Pharmaceuticals (AVIR) after Merck (MRK) provided an update on the development program for molnupiravir, an investigational oral antiviral for the treatment of COVID-19, was unwarranted. Based on a planned interim analysis, Merck decided to discontinue development of molnupiravir in hospitalized patients and to amend the inclusion criteria for the Phase III portion of the outpatient study, Lugo tells investors in a research note. Atea closed down by 15% as investors likely saw read-through from the "seemingly negative updates" from molnupiravir to the company's AT-527 development program, says the analyst. Lugo believes the negative reaction was overdone, noting the inclusion criteria for Atea's ongoing Phase II clinical trials of AT-527 for COVID-19 have always used the more stringent inclusion criteria. Further, while both AT-527 and molnupiravir are nucleoside analogs that target RdRp, they do so using slightly different approaches, says the analyst. Lugo keeps an Outperform rating on Atea Pharmaceuticals.

ShowHide Related Items >><<
MRK Merck
$76.67 /

+0.27 (+0.35%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
11/24/20 Morgan Stanley
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
11/24/20 JPMorgan
Atea Pharmaceuticals initiated with an Overweight at JPMorgan
MRK Merck
$76.67 /

+0.27 (+0.35%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
MRK Merck
$76.67 /

+0.27 (+0.35%)

  • 30
    Oct
MRK Merck
$76.67 /

+0.27 (+0.35%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

Thursday
On The Fly
Fly Intel: Wall Street's top stories for Thursday » 16:33
04/15/21
04/15
16:33
04/15/21
16:33
DELL

Dell Technologies

$98.90 /

+6.2 (+6.69%)

, VMW

VMware

$160.06 /

+4.57 (+2.94%)

, C

Citi

$72.53 /

-0.39 (-0.53%)

, BAC

Bank of America

$38.75 /

-1.15 (-2.88%)

, BLK

BlackRock

$818.24 /

+15.52 (+1.93%)

, UNH

UnitedHealth

$390.14 /

+14.39 (+3.83%)

, PEP

PepsiCo

$142.20 /

+ (+0.00%)

, DAL

Delta Air Lines

$46.83 /

-1.32 (-2.74%)

, TMO

Thermo Fisher

$494.70 /

+16.97 (+3.55%)

, PPD

PPD

$45.80 /

+3.3 (+7.76%)

, MRK

Merck

$76.67 /

+0.27 (+0.35%)

, PFE

Pfizer

$37.61 /

+0.45 (+1.21%)

, DNZ

D and Z Media Acquisition

$9.95 /

+0.045 (+0.45%)

, ICE

IntercontinentalExchange

$119.87 /

+1.695 (+1.43%)

, WRI

Weingarten Realty

$30.75 /

+3.375 (+12.33%)

, KIM

Kimco Realty

$19.92 /

+0.445 (+2.28%)

, WIT

Wipro

$6.55 /

+0.445 (+7.29%)

, SPCE

Virgin Galactic

$23.05 /

-3.6 (-13.51%)

, QS

QuantumScape

$35.86 /

-5.02 (-12.28%)

Stocks rose to record…

ShowHide Related Items >><<
WRI Weingarten Realty
$30.75 /

+3.375 (+12.33%)

WIT Wipro
$6.55 /

+0.445 (+7.29%)

UNH UnitedHealth
$390.14 /

+14.39 (+3.83%)

TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

SPCE Virgin Galactic
$23.05 /

-3.6 (-13.51%)

QS QuantumScape
$35.86 /

-5.02 (-12.28%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

PEP PepsiCo
$142.20 /

+ (+0.00%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

KIM Kimco Realty
$19.92 /

+0.445 (+2.28%)

ICE IntercontinentalExchange
$119.87 /

+1.695 (+1.43%)

DELL Dell Technologies
$98.90 /

+6.2 (+6.69%)

DAL Delta Air Lines
$46.83 /

-1.32 (-2.74%)

C Citi
$72.53 /

-0.39 (-0.53%)

BLK BlackRock
$818.24 /

+15.52 (+1.93%)

BAC Bank of America
$38.75 /

-1.15 (-2.88%)

DELL Dell Technologies
$98.90 /

+6.2 (+6.69%)

04/15/21 UBS
Dell Technologies price target raised to $110 from $90 at UBS
04/15/21 Evercore ISI
Dell Technologies price target raised to $110 from $105 at Evercore ISI
04/15/21 Wells Fargo
Dell Technologies price target raised to $120 from $90 at Wells Fargo
04/15/21 Northland
VMware downgraded to Market Perform from Outperform at Northland
VMW VMware
$160.06 /

+4.57 (+2.94%)

04/15/21
Fly Intel: Top five analyst downgrades
C Citi
$72.53 /

-0.39 (-0.53%)

04/13/21 Morgan Stanley
Citi price target raised to $89 from $81 at Morgan Stanley
04/09/21 Jefferies
Citi price target raised to $85 from $75 at Jefferies
04/07/21 Barclays
Citi price target raised to $84 from $77 at Barclays
04/05/21 Cowen
Risk to mortgage servicers rises as CFPB proposes foreclosure policy, says Cowen
BAC Bank of America
$38.75 /

-1.15 (-2.88%)

04/16/21 RBC Capital
Bank of America price target raised to $44 from $37 at RBC Capital
04/16/21 Baird
Bank of America price target raised to $42 from $38 at Baird
04/09/21 Jefferies
Bank of America price target raised to $41 from $33 at Jefferies
04/07/21 Barclays
Bank of America price target raised to $45 from $40 at Barclays
BLK BlackRock
$818.24 /

+15.52 (+1.93%)

04/16/21 Credit Suisse
BlackRock price target raised to $984 from $949 at Credit Suisse
04/16/21 Deutsche Bank
BlackRock price target raised to $912 from $847 at Deutsche Bank
04/16/21 Citi
BlackRock price target raised to $1,000 from $950 at Citi
04/16/21 Barclays
BlackRock price target raised to $925 from $850 at Barclays
UNH UnitedHealth
$390.14 /

+14.39 (+3.83%)

04/16/21 Morgan Stanley
UnitedHealth price target raised to $515 from $462 at Morgan Stanley
04/16/21 BMO Capital
UnitedHealth price target raised to $435 from $410 at BMO Capital
04/16/21 Oppenheimer
UnitedHealth price target raised to $440 from $375 at Oppenheimer
04/16/21 Deutsche Bank
UnitedHealth price target raised to $418 from $409 at Deutsche Bank
PEP PepsiCo
$142.20 /

+ (+0.00%)

04/16/21 Deutsche Bank
PepsiCo price target raised to $147 from $145 at Deutsche Bank
04/12/21 Wolfe Research
PepsiCo initiated with a Peer Perform at Wolfe Research
03/22/21
Fly Intel: Top five analyst upgrades
03/22/21 Barclays
PepsiCo upgraded to Overweight from Equal Weight at Barclays
DAL Delta Air Lines
$46.83 /

-1.32 (-2.74%)

04/15/21 Barclays
Delta Air Lines price target raised to $52 from $42 at Barclays
04/14/21 JPMorgan
Delta Air Lines price target raised to $63 from $49 at JPMorgan
04/09/21 Cowen
Delta Air Lines price target raised to $53 from $44 at Cowen
04/06/21 Morgan Stanley
Delta Air Lines price target raised to $72 from $55 at Morgan Stanley
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

04/16/21 Deutsche Bank
PPD downgraded to Hold from Buy at Deutsche Bank
04/16/21 William Blair
PPD downgraded to Market Perform from Outperform at William Blair
04/16/21 Evercore ISI
Thermo Fisher price target raised to $540 from $525 at Evercore ISI
04/16/21 KeyBanc
PPD downgraded to Sector Weight on takeover at KeyBanc
PPD PPD
$45.80 /

+3.3 (+7.76%)

04/16/21 Evercore ISI
PPD downgraded to In Line from Outperform at Evercore ISI
MRK Merck
$76.67 /

+0.27 (+0.35%)

04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
DNZ D and Z Media Acquisition
$9.95 /

+0.045 (+0.45%)

ICE IntercontinentalExchange
$119.87 /

+1.695 (+1.43%)

04/06/21 Raymond James
IntercontinentalExchange price target raised to $136 at Raymond James
01/12/21 Barclays
IntercontinentalExchange price target raised to $134 from $125 at Barclays
01/07/21 Piper Sandler
IntercontinentalExchange price target raised to $127 from $117 at Piper Sandler
12/22/20 Compass Point
IntercontinentalExchange price target raised to $125 from $110 at Compass Point
WRI Weingarten Realty
$30.75 /

+3.375 (+12.33%)

04/16/21 Mizuho
Kimco Realty price target raised to $22 from $20 at Mizuho
04/16/21 Piper Sandler
Urstadt Biddle upgraded to Overweight from Neutral at Piper Sandler
04/15/21 Scotiabank
Weingarten Realty downgraded to Sector Perform from Outperform at Scotiabank
04/15/21 Truist
Kimco Realty, Weingarten Realty merger 'a win-win for both,' says Truist
KIM Kimco Realty
$19.92 /

+0.445 (+2.28%)

04/15/21 Deutsche Bank
Kimco Realty price target raised to $21 from $17 at Deutsche Bank
WIT Wipro
$6.55 /

+0.445 (+7.29%)

04/16/21 Citi
Wipro upgraded to Buy from Neutral at Citi
04/16/21 Nomura
Wipro upgraded to Neutral from Reduce at Nomura
04/16/21 Citi
Wipro upgraded to Buy from Neutral at Citi
03/05/21 ICICI Securities
Wipro downgraded to Sell from Reduce at ICICI Securities
SPCE Virgin Galactic
$23.05 /

-3.6 (-13.51%)

04/12/21 Bernstein
Virgin Galactic initiated with a Market Perform at Bernstein
03/16/21 Truist
Truist starts 'uniquely positioned' Virgin Galactic at Buy with $50 price target
03/16/21 Truist
Virgin Galactic initiated with a Buy at Truist
03/03/21 BofA
Virgin Galactic price target raised to $50 from $35 at BofA
QS QuantumScape
$35.86 /

-5.02 (-12.28%)

03/08/21 Cowen
Cowen bullish on battery technology, starts QuantumScape at Outperform
03/08/21 Cowen
QuantumScape initiated with an Outperform at Cowen
03/04/21 Baird
QuantumScape initiated with a Neutral at Baird
02/11/21 Morgan Stanley
QuantumScape initiated with an Overweight at Morgan Stanley
WRI Weingarten Realty
$30.75 /

+3.375 (+12.33%)

WIT Wipro
$6.55 /

+0.445 (+7.29%)

VMW VMware
$160.06 /

+4.57 (+2.94%)

UNH UnitedHealth
$390.14 /

+14.39 (+3.83%)

TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

SPCE Virgin Galactic
$23.05 /

-3.6 (-13.51%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

PEP PepsiCo
$142.20 /

+ (+0.00%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

KIM Kimco Realty
$19.92 /

+0.445 (+2.28%)

ICE IntercontinentalExchange
$119.87 /

+1.695 (+1.43%)

DELL Dell Technologies
$98.90 /

+6.2 (+6.69%)

DAL Delta Air Lines
$46.83 /

-1.32 (-2.74%)

C Citi
$72.53 /

-0.39 (-0.53%)

BLK BlackRock
$818.24 /

+15.52 (+1.93%)

BAC Bank of America
$38.75 /

-1.15 (-2.88%)

  • 25
    Mar
  • 05
    Nov
  • 17
    Sep
  • 10
    Sep
  • 06
    Aug
  • 03
    Jun
  • 20
    May
  • 13
    May
VMW VMware
$160.06 /

+4.57 (+2.94%)

UNH UnitedHealth
$390.14 /

+14.39 (+3.83%)

TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

SPCE Virgin Galactic
$23.05 /

-3.6 (-13.51%)

QS QuantumScape
$35.86 /

-5.02 (-12.28%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

PEP PepsiCo
$142.20 /

+ (+0.00%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

ICE IntercontinentalExchange
$119.87 /

+1.695 (+1.43%)

DNZ D and Z Media Acquisition
$9.95 /

+0.045 (+0.45%)

DELL Dell Technologies
$98.90 /

+6.2 (+6.69%)

DAL Delta Air Lines
$46.83 /

-1.32 (-2.74%)

C Citi
$72.53 /

-0.39 (-0.53%)

BLK BlackRock
$818.24 /

+15.52 (+1.93%)

BAC Bank of America
$38.75 /

-1.15 (-2.88%)

VMW VMware
$160.06 /

+4.57 (+2.94%)

UNH UnitedHealth
$390.14 /

+14.39 (+3.83%)

TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

SPCE Virgin Galactic
$23.05 /

-3.6 (-13.51%)

QS QuantumScape
$35.86 /

-5.02 (-12.28%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

PEP PepsiCo
$142.20 /

+ (+0.00%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

ICE IntercontinentalExchange
$119.87 /

+1.695 (+1.43%)

DNZ D and Z Media Acquisition
$9.95 /

+0.045 (+0.45%)

DELL Dell Technologies
$98.90 /

+6.2 (+6.69%)

DAL Delta Air Lines
$46.83 /

-1.32 (-2.74%)

C Citi
$72.53 /

-0.39 (-0.53%)

BLK BlackRock
$818.24 /

+15.52 (+1.93%)

VMW VMware
$160.06 /

+4.57 (+2.94%)

UNH UnitedHealth
$390.14 /

+14.39 (+3.83%)

SPCE Virgin Galactic
$23.05 /

-3.6 (-13.51%)

QS QuantumScape
$35.86 /

-5.02 (-12.28%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

PEP PepsiCo
$142.20 /

+ (+0.00%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

KIM Kimco Realty
$19.92 /

+0.445 (+2.28%)

DELL Dell Technologies
$98.90 /

+6.2 (+6.69%)

DAL Delta Air Lines
$46.83 /

-1.32 (-2.74%)

C Citi
$72.53 /

-0.39 (-0.53%)

BAC Bank of America
$38.75 /

-1.15 (-2.88%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:51
04/15/21
04/15
12:51
04/15/21
12:51
DELL

Dell Technologies

$101.15 /

+8.45 (+9.12%)

, VMW

VMware

$161.62 /

+6.13 (+3.94%)

, TMO

Thermo Fisher

$496.64 /

+18.91 (+3.96%)

, PPD

PPD

$45.90 /

+3.4 (+8.00%)

, C

Citi

$72.90 /

-0.02 (-0.03%)

, BAC

Bank of America

$38.71 /

-1.195 (-2.99%)

, PEP

PepsiCo

$142.38 /

+0.18 (+0.13%)

, DAL

Delta Air Lines

$46.49 /

-1.66 (-3.45%)

, UNH

UnitedHealth

$388.10 /

+12.35 (+3.29%)

, MRK

Merck

$76.65 /

+0.25 (+0.33%)

, WRI

Weingarten Realty

$30.22 /

+2.845 (+10.39%)

, KIM

Kimco Realty

$19.47 /

-0.005 (-0.03%)

, WIT

Wipro

$6.46 /

+0.355 (+5.81%)

, GBOX

GreenBox

$10.13 /

-3.48 (-25.57%)

, SPCE

Virgin Galactic

$23.23 /

-3.42 (-12.83%)

The major averages are…

ShowHide Related Items >><<
WRI Weingarten Realty
$30.22 /

+2.845 (+10.39%)

WIT Wipro
$6.46 /

+0.355 (+5.81%)

UNH UnitedHealth
$388.10 /

+12.35 (+3.29%)

TMO Thermo Fisher
$496.64 /

+18.91 (+3.96%)

SPCE Virgin Galactic
$23.23 /

-3.42 (-12.83%)

PPD PPD
$45.90 /

+3.4 (+8.00%)

PEP PepsiCo
$142.38 /

+0.18 (+0.13%)

MRK Merck
$76.65 /

+0.25 (+0.33%)

KIM Kimco Realty
$19.47 /

-0.005 (-0.03%)

GBOX GreenBox
$10.13 /

-3.48 (-25.57%)

DELL Dell Technologies
$101.15 /

+8.45 (+9.12%)

DAL Delta Air Lines
$46.49 /

-1.66 (-3.45%)

C Citi
$72.90 /

-0.02 (-0.03%)

BAC Bank of America
$38.71 /

-1.195 (-2.99%)

DELL Dell Technologies
$101.15 /

+8.45 (+9.12%)

04/15/21 UBS
Dell Technologies price target raised to $110 from $90 at UBS
04/15/21 Evercore ISI
Dell Technologies price target raised to $110 from $105 at Evercore ISI
04/15/21 Wells Fargo
Dell Technologies price target raised to $120 from $90 at Wells Fargo
04/15/21 Northland
VMware downgraded to Market Perform from Outperform at Northland
VMW VMware
$161.62 /

+6.13 (+3.94%)

04/15/21
Fly Intel: Top five analyst downgrades
TMO Thermo Fisher
$496.64 /

+18.91 (+3.96%)

04/15/21 Citi
Thermo Fisher deal for PPD would make sense, says Citi
03/29/21 UBS
Thermo Fisher price target lowered to $560 from $588 at UBS
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
PPD PPD
$45.90 /

+3.4 (+8.00%)

04/15/21 Baird
PPD downgraded to Neutral from Outperform at Baird
03/02/21 Barclays
PPD initiated with an Overweight at Barclays
03/02/21 Barclays
PPD initiated with an Overweight at Barclays
C Citi
$72.90 /

-0.02 (-0.03%)

04/13/21 Morgan Stanley
Citi price target raised to $89 from $81 at Morgan Stanley
04/09/21 Jefferies
Citi price target raised to $85 from $75 at Jefferies
04/07/21 Barclays
Citi price target raised to $84 from $77 at Barclays
04/05/21 Cowen
Risk to mortgage servicers rises as CFPB proposes foreclosure policy, says Cowen
BAC Bank of America
$38.71 /

-1.195 (-2.99%)

04/09/21 Jefferies
Bank of America price target raised to $41 from $33 at Jefferies
04/07/21 Barclays
Bank of America price target raised to $45 from $40 at Barclays
04/01/21 Deutsche Bank
Bank of America price target raised to $44 from $35 at Deutsche Bank
PEP PepsiCo
$142.38 /

+0.18 (+0.13%)

04/12/21 Wolfe Research
PepsiCo initiated with a Peer Perform at Wolfe Research
03/22/21
Fly Intel: Top five analyst upgrades
03/22/21 Barclays
PepsiCo upgraded to Overweight from Equal Weight at Barclays
03/11/21 Morgan Stanley
Morgan Stanley downgrades Keurig Dr Pepper to Equal Weight after outperformance
DAL Delta Air Lines
$46.49 /

-1.66 (-3.45%)

04/15/21 Barclays
Delta Air Lines price target raised to $52 from $42 at Barclays
04/14/21 JPMorgan
Delta Air Lines price target raised to $63 from $49 at JPMorgan
04/09/21 Cowen
Delta Air Lines price target raised to $53 from $44 at Cowen
04/06/21 Morgan Stanley
Delta Air Lines price target raised to $72 from $55 at Morgan Stanley
UNH UnitedHealth
$388.10 /

+12.35 (+3.29%)

04/14/21 Truist
UnitedHealth price target raised to $450 from $420 at Truist
04/09/21 Mizuho
UnitedHealth price target raised to $394 from $380 at Mizuho
03/17/21 Stephens
Amazon news latest sign of rising telehealth competition, says Stephens
01/28/21 Stephens
Anthem price target lowered to $340 from $350 at Stephens
MRK Merck
$76.65 /

+0.25 (+0.33%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
WRI Weingarten Realty
$30.22 /

+2.845 (+10.39%)

04/15/21 Truist
Kimco Realty, Weingarten Realty merger 'a win-win for both,' says Truist
04/13/21 Baird
Weingarten Realty reinstated with an Outperform at Baird
03/09/21 BTIG
Weingarten Realty price target raised to $28 from $25 at BTIG
03/05/21 Truist
Weingarten Realty price target raised to $28 from $24 at Truist
KIM Kimco Realty
$19.47 /

-0.005 (-0.03%)

04/15/21 Deutsche Bank
Kimco Realty price target raised to $21 from $17 at Deutsche Bank
04/14/21 Baird
Kimco Realty assumed with an Outperform at Baird
04/13/21 Baird
Kimco Realty reinstated with an Outperform at Baird
WIT Wipro
$6.46 /

+0.355 (+5.81%)

03/05/21 ICICI Securities
Wipro downgraded to Sell from Reduce at ICICI Securities
12/21/20 Goldman Sachs
Wipro resumed with a Sell at Goldman Sachs
10/14/20 Investec
Wipro downgraded to Hold from Buy at Investec
10/06/20 ICICI Securities
Wipro downgraded to Hold from Buy at ICICI Securities
GBOX GreenBox
$10.13 /

-3.48 (-25.57%)

SPCE Virgin Galactic
$23.23 /

-3.42 (-12.83%)

04/12/21 Bernstein
Virgin Galactic initiated with a Market Perform at Bernstein
03/16/21 Truist
Truist starts 'uniquely positioned' Virgin Galactic at Buy with $50 price target
03/16/21 Truist
Virgin Galactic initiated with a Buy at Truist
03/03/21 BofA
Virgin Galactic price target raised to $50 from $35 at BofA
WRI Weingarten Realty
$30.22 /

+2.845 (+10.39%)

WIT Wipro
$6.46 /

+0.355 (+5.81%)

VMW VMware
$161.62 /

+6.13 (+3.94%)

UNH UnitedHealth
$388.10 /

+12.35 (+3.29%)

TMO Thermo Fisher
$496.64 /

+18.91 (+3.96%)

SPCE Virgin Galactic
$23.23 /

-3.42 (-12.83%)

PPD PPD
$45.90 /

+3.4 (+8.00%)

PEP PepsiCo
$142.38 /

+0.18 (+0.13%)

MRK Merck
$76.65 /

+0.25 (+0.33%)

KIM Kimco Realty
$19.47 /

-0.005 (-0.03%)

DELL Dell Technologies
$101.15 /

+8.45 (+9.12%)

DAL Delta Air Lines
$46.49 /

-1.66 (-3.45%)

C Citi
$72.90 /

-0.02 (-0.03%)

BAC Bank of America
$38.71 /

-1.195 (-2.99%)

  • 17
    Feb
  • 17
    Sep
  • 06
    Aug
  • 03
    Jun
  • 20
    May
VMW VMware
$161.62 /

+6.13 (+3.94%)

UNH UnitedHealth
$388.10 /

+12.35 (+3.29%)

TMO Thermo Fisher
$496.64 /

+18.91 (+3.96%)

SPCE Virgin Galactic
$23.23 /

-3.42 (-12.83%)

PEP PepsiCo
$142.38 /

+0.18 (+0.13%)

MRK Merck
$76.65 /

+0.25 (+0.33%)

GBOX GreenBox
$10.13 /

-3.48 (-25.57%)

DELL Dell Technologies
$101.15 /

+8.45 (+9.12%)

DAL Delta Air Lines
$46.49 /

-1.66 (-3.45%)

C Citi
$72.90 /

-0.02 (-0.03%)

BAC Bank of America
$38.71 /

-1.195 (-2.99%)

VMW VMware
$161.62 /

+6.13 (+3.94%)

UNH UnitedHealth
$388.10 /

+12.35 (+3.29%)

TMO Thermo Fisher
$496.64 /

+18.91 (+3.96%)

SPCE Virgin Galactic
$23.23 /

-3.42 (-12.83%)

PPD PPD
$45.90 /

+3.4 (+8.00%)

PEP PepsiCo
$142.38 /

+0.18 (+0.13%)

MRK Merck
$76.65 /

+0.25 (+0.33%)

GBOX GreenBox
$10.13 /

-3.48 (-25.57%)

DELL Dell Technologies
$101.15 /

+8.45 (+9.12%)

DAL Delta Air Lines
$46.49 /

-1.66 (-3.45%)

C Citi
$72.90 /

-0.02 (-0.03%)

BAC Bank of America
$38.71 /

-1.195 (-2.99%)

VMW VMware
$161.62 /

+6.13 (+3.94%)

UNH UnitedHealth
$388.10 /

+12.35 (+3.29%)

SPCE Virgin Galactic
$23.23 /

-3.42 (-12.83%)

PEP PepsiCo
$142.38 /

+0.18 (+0.13%)

MRK Merck
$76.65 /

+0.25 (+0.33%)

KIM Kimco Realty
$19.47 /

-0.005 (-0.03%)

DELL Dell Technologies
$101.15 /

+8.45 (+9.12%)

DAL Delta Air Lines
$46.49 /

-1.66 (-3.45%)

C Citi
$72.90 /

-0.02 (-0.03%)

BAC Bank of America
$38.71 /

-1.195 (-2.99%)

Hot Stocks
Nabriva announces start of exclusive distribution of Sivextro in U.S. » 12:15
04/15/21
04/15
12:15
04/15/21
12:15
NBRV

Nabriva Therapeutics

$1.45 /

-0.03 (-2.03%)

, MRK

Merck

$76.97 /

+0.57 (+0.75%)

Nabriva Therapeutics…

Nabriva Therapeutics (NBRV) announced that it has begun exclusive distribution of Sivextro in the United States. Sivextro is now listed in the National Drug Code Directory under the Nabriva label. Since April 12, 2021, Nabriva has been marketing and distributing Sivextro in the United States and certain of its territories as part of an exclusive agreement signed in July 2020 with subsidiaries of Merck (MRK), the company noted. Under the terms of the agreement with Merck, Nabriva will continue to procure Sivextro from Merck and be solely responsible for marketing, sales, and distribution of Sivextro in the United States at least through December 31, 2023, with renewable three-year extensions. As a result, Nabriva expects to recognize 100% of net product sales of Sivextro in its results of operations beginning on April 12, 2021, the company said.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

03/12/21 Northland
Nabriva Therapeutics price target lowered to $6 from $9 at Northland
06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
MRK Merck
$76.97 /

+0.57 (+0.75%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

  • 11
    Dec
MRK Merck
$76.97 /

+0.57 (+0.75%)

NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

Options
Merck call volume above normal and directionally bullish » 11:25
04/15/21
04/15
11:25
04/15/21
11:25
MRK

Merck

$77.20 /

+0.8 (+1.05%)

Bullish option flow…

Bullish option flow detected in Merck with 11,614 calls trading, 1.4x expected, and implied vol increasing almost 9 points to 26.87%. May-21 82.5 calls and Apr-21 78 calls are the most active options, with total volume in those strikes near 4,600 contracts. The Put/Call Ratio is 0.30. Earnings are expected on April 29th.

ShowHide Related Items >><<
MRK Merck
$77.20 /

+0.8 (+1.05%)

MRK Merck
$77.20 /

+0.8 (+1.05%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
MRK Merck
$77.20 /

+0.8 (+1.05%)

MRK Merck
$77.20 /

+0.8 (+1.05%)

MRK Merck
$77.20 /

+0.8 (+1.05%)

MRK Merck
$77.20 /

+0.8 (+1.05%)

Hot Stocks
Sutro Biopharma earns $15M milestone payment from Merck » 07:04
04/15/21
04/15
07:04
04/15/21
07:04
STRO

Sutro Biopharma

$19.88 /

+0.83 (+4.36%)

, MRK

Merck

$76.40 /

-0.01 (-0.01%)

Sutro Biopharma (STRO)…

Sutro Biopharma (STRO) announced that Merck (MRK) will make to Sutro a $15M milestone payment for the initiation of an IND enabling toxicology study for the first program in its collaboration to develop novel cytokine derivative therapeutics for cancer and autoimmune disorders. In July 2018, Sutro entered into a collaboration with Merck to jointly discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.

ShowHide Related Items >><<
STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MRK Merck
$76.40 /

-0.01 (-0.01%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

  • 09
    Dec
  • 12
    May
MRK Merck
$76.40 /

-0.01 (-0.01%)

STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

Hot Stocks
Merck to discontinue development of MRK-7110 in COVID-19 treatment » 06:54
04/15/21
04/15
06:54
04/15/21
06:54
MRK

Merck

$76.40 /

-0.01 (-0.01%)

, JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

The company states:…

The company states: "Merck (MRK) announced the discontinuation of development of MK-7110 for the treatment of hospitalized patients with COVID-19. Merck acquired MK-7110 in December 2020 through its acquisition of OncoImmune, a privately-held clinical-stage biopharmaceutical company. As previously reported, Merck subsequently received feedback from the US Food and Drug Administration that additional data, beyond the study conducted by OncoImmune, would be needed to support a potential Emergency Use Authorization application. Based on the additional research that would be required - new clinical trials as well as research related to manufacturing at scale - MK-7110 would not be expected to become available until the first half of 2022. Given this timeline and these technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck's resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck has determined to discontinue development of MK-7110 for COVID-19 and to focus its pandemic efforts on advancing molnupiravir and on producing Johnson & Johnson's (JNJ) COVID-19 vaccine."

ShowHide Related Items >><<
MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

Hot Stocks
Merck to proceed with Ph3 study of molnupiravir in outpatients, not inpatients » 06:49
04/15/21
04/15
06:49
04/15/21
06:49
MRK

Merck

$76.40 /

-0.01 (-0.01%)

Merck provided an update…

Merck provided an update on the clinical development program for molnupiravir, an investigational orally available antiviral therapeutic. Based on a planned interim analysis of data from the Phase 2, dose-finding portion of two ongoing placebo-controlled Phase 2/3 trials evaluating molnupiravir administered twice a day for five days in outpatients and hospitalized patients with COVID-19, and from a previously completed Phase 2a dose-ranging study in outpatients, the decision has been made to proceed with the Phase 3 portion of MOVe-OUT in outpatients with COVID-19, evaluating the 800 mg dose of molnupiravir twice daily. Data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalized patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision has been made not to proceed to Phase 3.

ShowHide Related Items >><<
MRK Merck
$76.40 /

-0.01 (-0.01%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
MRK Merck
$76.40 /

-0.01 (-0.01%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

Tuesday
Conference/Events
FDA PDUFA Date for Merck Keytruda with Chemotherapy is April 13, 2021  08:52
04/13/21
04/13
08:52
04/13/21
08:52
MRK

Merck

$76.23 /

-0.095 (-0.12%)

 
ShowHide Related Items >><<
MRK Merck
$76.23 /

-0.095 (-0.12%)

MRK Merck
$76.23 /

-0.095 (-0.12%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
MRK Merck
$76.23 /

-0.095 (-0.12%)

MRK Merck
$76.23 /

-0.095 (-0.12%)

MRK Merck
$76.23 /

-0.095 (-0.12%)

MRK Merck
$76.23 /

-0.095 (-0.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.